SIRT1/Nrf2 and PI3K/AKT signaling pathways are two of the key network pathways in which sotagliflozin exhibits additional therapeutic benefits when used to modify the pathophysiology of liver fibrosis. The gene discussed is AKT1; the disease is Hepatic fibrosis.